Ceva Santé Animale has acquired Sogeval, a subsidiary of French industrial and financial company Sofiprotéol, the companies announced today. Under the agreement, Sogeval becomes a subsidiary of Ceva.
“Sogeval is known for high-quality products in categories that have a great deal of consumer interest and growth potential,” says Craig Wallace, Ceva’s North American CEO. “We are eager to move forward with the integration.”
The aim of the acquisition is to accelerate growth, Ceva states in a company release. Ceva and Sogeval will coordinate their respective distribution networks and subsidiaries in an attempt to boost positions in all markets.
“For now it is business as usual,” Wallace says. “It will take some time to determine the best route to unite our common interests in a manner that is as seamless as possible for customers. Business conducted with Ceva and Sogeval will continue as it always has for the immediate future.”
Future operations will grow and develop from complementary expertise, the companies state. For example, Sogeval focuses on antibiotherapy and dermatology, while Ceva is noted for its antiparasitics and animal behavior products. Both companies have a presence in cardiology and pain management, allowing them to maximize efforts in those categories. And Ceva and Sogeval have both developed vaccines and reproductive products for livestock.
Both companies are headquartered in France.